- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP (clinicaltrials.gov) - Apr 21, 2016 P3, N=123, Completed, N=199 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | N=240 --> 123 | Trial primary completion date: Sep 2013 --> Dec 2013
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 21, 2016 P3, N=91, Completed, Recruiting --> Completed | N=240 --> 123 | Trial primary completion date: Sep 2013 --> Dec 2013 Recruiting --> Completed | N=200 --> 91 | Trial primary completion date: Sep 2012 --> Aug 2013
- |||||||||| Trial completion, Enrollment change: Autoantibody Specificity and Response to IVIG in ITP (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=672, Completed, Recruiting --> Completed | N=200 --> 158 | Trial primary completion date: Jul 2013 --> Jul 2014 Recruiting --> Completed | N=200 --> 672
- |||||||||| dexamethasone / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Caffeic Acid Tablets as a Second-line Therapy for ITP (clinicaltrials.gov) - Apr 20, 2016 P3, N=103, Completed, N=240 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | Initiation date: Dec 2014 --> Sep 2012 | Trial primary completion date: Mar 2016 --> Dec 2013
- |||||||||| Enrollment closed, Enrollment change, Trial primary completion date: BIOFLOW III Asia Registry Orsiro Stent System (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=364, Active, not recruiting, N=81 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=880 --> 364 | Trial primary completion date: Sep 2015 --> Apr 2017
- |||||||||| mocravimod (KRP-203) / Priothera
Trial completion, Enrollment change: Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Apr 18, 2016 P2, N=10, Completed, Recruiting --> Active, not recruiting | N=880 --> 364 | Trial primary completion date: Sep 2015 --> Apr 2017 Terminated --> Completed | N=22 --> 10
- |||||||||| opicinumab (BIIB033) / Biogen, Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: SYNERGY: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (clinicaltrials.gov) - Apr 16, 2016 P2, N=419, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
Trial completion: Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 15, 2016 P2, N=43, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Trial primary completion date: Power Over Pain (POP) Study (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=144, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Jan 2017
|